期刊文献+

表达人γ-干扰素的重组腺病毒的制备及检测 被引量:2

Construction and Identification of Recombinant Adenovirus for Expressing Human Interferon γ
暂未订购
导出
摘要 E1区缺失的腺病毒载体插入人γ干扰素cDNA序列,与pJM17质粒通过磷酸钙沉淀法共转染293细胞,经同源重组,共获得6个病毒噬斑。经PCR共扩增检测,证实这6个噬斑均为带有人γ干扰素cDNA的重组腺病毒;受其感染的293细胞的上清中,都能测到γ干扰素的活性,且这种活性可被一定稀释度的兔抗人γ干扰素多克隆抗体所中和。其中的1号重组病毒纯化后,按不同的MOI(Multipleofinfection)值感染复制缺陷型腺病毒不能在其中增殖的B16F10细胞,未出现细胞病变效应(Cytopathicefect,CPE),而上清中的γ干扰素活性却随MOI值增大而升高。 E1 deleted adenoviral vector,pAdl2/RSV IFN bpA,harboring human IFN γ cDNA, and plasmid pJM17 were co transfected into human embryo kidney cell line 293 cells by calcium phosphate precipitation mediated transfection. Six strains of recombinant adenoviruses(rAd) were obtained after 11 day's incubation. PCR analysis indicated that all six rAds contained human IFN γ cDNA. The biological activity of IFN γ was detected in the supernatant of the cultured 293 cells following rAds' infection, and it could be blocked by the antibody for IFN γ . The B16F10 cells infected with the purified rAd(RSV/IFN 01 ) didn't show cytopathic effect (CPE),and the more biological activity of INF γ was detected in the infected B16F10 cells' supernatant with the increased MOI(multiple of infection) values. Therefore,the recombinant adenovirus constructed in this study can express and secrete human IFN γ
出处 《生物工程学报》 CAS CSCD 北大核心 1997年第1期6-12,共7页 Chinese Journal of Biotechnology
基金 利诚-复旦生物高新技术基金
关键词 基因治疗 腺病毒 Γ-干扰素 同源重组 活性检测 Adenovirus, IFN γ , homologous recombination,bioassay
  • 相关文献

参考文献1

  • 1Fang B,Proc Natl Acad USA,1995年,92卷,2577页

同被引文献31

  • 1周圆,金冬雁,曾庆,李玉英,迟捷,侯云德.重组人α2b型干扰素的纯化与鉴定[J].生物工程学报,1994,10(1):61-65. 被引量:6
  • 2张彤,吴淑华,张鹤龄,侯云德.干扰素α—2b的高效表达及原核增强子效应研究[J].病毒学报,1995,11(2):131-137. 被引量:5
  • 3陈勇,陈妍.重组干扰素α1b壳聚糖涂膜剂的制备及质量控制[J].中国药房,2006,17(1):27-28. 被引量:7
  • 4中国药典(三部).北京:中国医药科技出版社,2010,附录XC.
  • 5Hak-Kim C, Andy C, Igor G, et al . Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery, pharmaceutical research, 1997 ,4 (14) :431-437.
  • 6Hiroaki T, Hirokazu O, Kotaro I, et al. Improvement of stability and absorbability of dry insulin powder for inhalation by powderconbination technique. International Journal of Pharmaceutics, 2004,3(271 ) :41-52.
  • 7Yuh-Fun M, Phuong-Anh N, Theresa S, et al. Protein inhalation powders: spray drying vs spray freeze drying. Pharmaceutical Research, 1999,2 ( 16 ) : 249 -254.
  • 8那伊.蛋白质药物-开发与生产.北京:化学工业出版社,2006,28.
  • 9中国药典(二部).北京:中国医药科技出版社,2010,附录IL.
  • 10国家食品药品监督管理局.吸入制剂质量控制研究技术指导原则.2007,1-24.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部